Kerry J. Savage

37.9k total citations · 7 hit papers
305 papers, 13.4k citations indexed

About

Kerry J. Savage is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Kerry J. Savage has authored 305 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 266 papers in Pathology and Forensic Medicine, 149 papers in Oncology and 76 papers in Genetics. Recurrent topics in Kerry J. Savage's work include Lymphoma Diagnosis and Treatment (266 papers), CNS Lymphoma Diagnosis and Treatment (69 papers) and Chronic Lymphocytic Leukemia Research (66 papers). Kerry J. Savage is often cited by papers focused on Lymphoma Diagnosis and Treatment (266 papers), CNS Lymphoma Diagnosis and Treatment (69 papers) and Chronic Lymphocytic Leukemia Research (66 papers). Kerry J. Savage collaborates with scholars based in Canada, United States and Italy. Kerry J. Savage's co-authors include Joseph M. Connors, Randy D. Gascoyne, Laurie H. Sehn, Richard Klasa, Mukesh Chhanabhai, Tamara Shenkier, Diego Villa, Stefano Pileri, Stephen M. Ansell and Paul Hoskins and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kerry J. Savage

283 papers receiving 13.1k citations

Hit Papers

The revised International... 2003 2026 2010 2018 2006 2012 2008 2003 2018 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    2006 1.0k citations Laurie H. Sehn, Mukesh Chhanabhai et al. Blood profile →
  2. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
    2012 1.0k citations Anas Younes, Ajay K. Gopal et al. Journal of Clinical Oncology profile →
  3. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
    2008 583 citations Kerry J. Savage, Julie M. Vose et al. Blood profile →
  4. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
    2003 570 citations Kerry J. Savage Blood profile →
  5. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
    2018 455 citations Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology profile →
  6. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
    2011 439 citations Owen A. O’Connor, Barbara Pro et al. Journal of Clinical Oncology profile →
  7. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
    2015 386 citations Owen A. O’Connor, Steven M. Horwitz et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kerry J. Savage Canada 51 10.6k 7.4k 3.4k 3.0k 2.8k 305 13.4k
Laurie H. Sehn Canada 55 10.6k 1.0× 7.3k 1.0× 3.1k 0.9× 4.2k 1.4× 1.9k 0.7× 353 13.4k
Nancy L. Bartlett United States 64 11.2k 1.1× 10.0k 1.4× 2.8k 0.8× 3.3k 1.1× 3.2k 1.1× 480 16.8k
Armando López‐Guillermo Spain 55 8.4k 0.8× 5.2k 0.7× 2.0k 0.6× 4.4k 1.5× 2.4k 0.9× 244 11.5k
Jonathan W. Friedberg United States 61 9.1k 0.9× 6.5k 0.9× 2.4k 0.7× 3.8k 1.3× 1.9k 0.7× 393 12.7k
Martin Dreyling Germany 52 10.3k 1.0× 7.2k 1.0× 2.2k 0.6× 4.8k 1.6× 1.6k 0.6× 396 13.1k
Corinne Haïoun France 70 14.0k 1.3× 8.4k 1.1× 3.5k 1.0× 4.6k 1.5× 2.9k 1.0× 400 17.7k
Franck Morschhauser France 56 8.8k 0.8× 6.7k 0.9× 1.8k 0.5× 3.7k 1.2× 2.3k 0.8× 447 12.3k
Won Seog Kim South Korea 48 7.1k 0.7× 6.3k 0.9× 1.4k 0.4× 1.8k 0.6× 3.0k 1.1× 462 10.8k
Luis Fayad United States 50 6.3k 0.6× 5.5k 0.7× 1.3k 0.4× 2.7k 0.9× 1.7k 0.6× 334 9.7k
Eric D. Hsi United States 62 6.0k 0.6× 4.7k 0.6× 1.4k 0.4× 3.5k 1.2× 2.6k 0.9× 405 12.2k

Countries citing papers authored by Kerry J. Savage

Since Specialization
Citations

This map shows the geographic impact of Kerry J. Savage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerry J. Savage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerry J. Savage more than expected).

Fields of papers citing papers by Kerry J. Savage

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerry J. Savage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerry J. Savage. The network helps show where Kerry J. Savage may publish in the future.

Co-authorship network of co-authors of Kerry J. Savage

This figure shows the co-authorship network connecting the top 25 collaborators of Kerry J. Savage. A scholar is included among the top collaborators of Kerry J. Savage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerry J. Savage. Kerry J. Savage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Villa, Diego, R. Petter Tonseth, Alina S. Gerrie, et al.. (2024). Long‐term follow‐up of bulky classic Hodgkin lymphoma managed with ABVD and PET‐guided RT demonstrates excellent outcomes in PET‐negative cases. British Journal of Haematology. 206(1). 167–171.
2.
Zinzani, Pier Luigi, Gilles Salles, Alison J. Moskowitz, et al.. (2024). Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Blood Advances. 8(10). 2400–2404. 4 indexed citations
3.
Yousefirizi, Fereshteh, Ivan S. Klyuzhin, R. Petter Tonseth, et al.. (2024). Evaluating Outcome Prediction via Baseline, End-of-Treatment, and Delta Radiomics on PET-CT Images of Primary Mediastinal Large B-Cell Lymphoma. Cancers. 16(6). 1090–1090. 13 indexed citations
4.
Angeles, Arkhjamil, Thao Phuong Nguyen, Gaurav Bahl, et al.. (2024). Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors.. Journal of Clinical Oncology. 42(16_suppl). 12047–12047. 2 indexed citations
5.
Bisig, Bettina, Kerry J. Savage, & Laurence de Leval. (2023). Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions. Haematologica. 108(12). 3227–3243. 12 indexed citations
6.
Pophali, Priyanka A., Lindsay M. Morton, Susan K. Parsons, et al.. (2023). Critical gaps in understanding treatment outcomes in adolescents and young adults with lymphoma: A review of current data. SHILAP Revista de lepidopterología. 4(4). 927–933. 2 indexed citations
7.
8.
Villa, Diego, Ciara L. Freeman, Graham W. Slack, et al.. (2022). Clinicopathological characteristics and long‐term outcomes of plasmablastic lymphoma in British Columbia. British Journal of Haematology. 199(2). 230–238. 6 indexed citations
9.
Miller, Wilson H., et al.. (2021). Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements. Current Oncology. 28(5). 3537–3553. 7 indexed citations
10.
Herrera, Alex F., Carmelo Carlo‐Stella, Graham P. Collins, et al.. (2020). Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. 136(Supplement 1). 21–23. 14 indexed citations
11.
Ramchandren, Radhakrishnan, Ranjana H. Advani, Stephen M. Ansell, et al.. (2019). Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research. 25(6). 1718–1726. 30 indexed citations
12.
Armand, Philippe, Andreas Engert, Anas Younes, et al.. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. Journal of Clinical Oncology. 36(14). 1428–1439. 455 indexed citations breakdown →
13.
O’Connor, Owen A., Steven M. Horwitz, Tamás Masszi, et al.. (2015). Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal of Clinical Oncology. 33(23). 2492–2499. 386 indexed citations breakdown →
14.
15.
Mak, Vivien, Mukesh Chhanabhai, Tamara Shenkier, et al.. (2013). Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. Journal of Clinical Oncology. 31(16). 1970–1976. 286 indexed citations
16.
Younes, Anas, Ajay K. Gopal, Scott E. Smith, et al.. (2012). Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology. 30(18). 2183–2189. 1014 indexed citations breakdown →
17.
Petrella, Teresa M., Richard Tozer, Karl Bélanger, et al.. (2012). Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study. Journal of Clinical Oncology. 30(27). 3396–3401. 95 indexed citations
18.
O’Connor, Owen A., Barbara Pro, Lauren Pinter‐Brown, et al.. (2011). Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. Journal of Clinical Oncology. 29(9). 1182–1189. 439 indexed citations breakdown →
19.
Savage, Kerry J., Nathalie A. Johnson, Susana Ben‐Neriah, et al.. (2009). MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 114(17). 3533–3537. 442 indexed citations
20.
Johnson, Nathalie A., Kerry J. Savage, Olga Ludkovski, et al.. (2009). Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 114(11). 2273–2279. 414 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laurie H. Sehn Breakdown of academic impact, for papers by Nancy L. Bartlett Breakdown of academic impact, for papers by Armando López‐Guillermo Breakdown of academic impact, for papers by Jonathan W. Friedberg Breakdown of academic impact, for papers by Martin Dreyling Breakdown of academic impact, for papers by Corinne Haïoun Breakdown of academic impact, for papers by Franck Morschhauser Breakdown of academic impact, for papers by Won Seog Kim Breakdown of academic impact, for papers by Luis Fayad Breakdown of academic impact, for papers by Eric D. Hsi
Rankless by CCL
2026